Large International Study Identifies 36 Risk Genes Across OCD and Chronic Tic Disorders

What the researchers found

Researchers analyzed whole-exome sequencing data from 3,964 people with obsessive–compulsive disorder (OCD), chronic tic disorders (CTDs), or both. The study included 2,418 parent–child trios and 1,546 additional individuals without parental sequencing data, alongside control groups.

Across separate and combined analyses, the researchers identified 36 high-confidence genes associated with OCD, chronic tic disorders, or both. That is a substantial expansion over the four high-confidence genes previously identified through whole-exome sequencing.

Chronic tic disorders include Tourette disorder. Many advocacy and clinical organizations use the term Tourette syndrome; this explainer follows the study's terminology when describing its methods and findings.

How the study was conducted

The researchers used whole-exome sequencing, which focuses on the protein-coding portions of the genome. They examined rare de novo variants, rare inherited variants, and rare variants found in participants for whom parental sequencing was not available.

The analysis focused on variants predicted to have damaging effects on proteins. The researchers then used a Bayesian gene-discovery framework called TADA to combine evidence across variant classes while accounting for gene-specific mutation rates and other factors.

The study's scale matters. It roughly doubled previous case sample sizes used in this area of whole-exome research, giving the investigators more statistical power to identify genes associated with relatively rare, large-effect variants.

What the shared genetics may mean

OCD and chronic tic disorders often occur together, and earlier research has suggested that they share some genetic risk. This study strengthens that picture.

Thirty of the 36 high-confidence genes had evidence contributed by both OCD and chronic tic disorder cases. The researchers also found overlap between some of these genes and genes implicated in other neurodevelopmental and psychiatric conditions, including autism, developmental delay or intellectual disability, and schizophrenia.

The study also examined where and when the identified genes are expressed. The researchers reported patterns involving the cortex, striatum, thalamus, and cerebellum across prenatal and postnatal development. Network analyses suggested that many of the genes participate in connected biological processes rather than acting as isolated genetic switches.

That kind of convergence is scientifically useful because it may help researchers move from lists of genes toward testable hypotheses about brain development, cell types, circuits, and molecular pathways.

What this means for individuals and families

The most important practical point is also the easiest one to lose in a genetics headline: these rare variants explain only a minority of cases.

At the individual level, the researchers estimated that about 7–8% of participants with OCD and/or chronic tic disorders carried at least one risk-contributing de novo damaging variant of the type studied. In an OCD singleton analysis, about 3% carried a rare likely gene-disrupting variant estimated to contribute to risk.

In other words, most people with OCD or chronic tic disorders will not have one of these particular large-effect variants. The study also estimated that hundreds of genes may ultimately contribute to risk, which is another reminder that the genetic architecture is broad and incomplete.

This research may eventually help scientists identify biological subgroups, clarify mechanisms, and investigate new treatment targets. But those are research directions. The paper does not establish a new clinical genetic test, a new diagnostic pathway, or a new treatment for OCD, chronic tic disorders, or Tourette disorder.

Why this study matters

The value of this study is not that genetics suddenly explains OCD or Tourette syndrome. It does not. The value is that a much larger international dataset gives researchers a clearer map of several rare, large-effect routes into conditions that have long appeared genetically connected.

That map is still incomplete. But moving from four high-confidence genes to 36 gives researchers more places to investigate how genetic variation may converge on developing brain systems and how those pathways might eventually inform more precise biological models.

Science is exciting enough without making it wear a fake mustache. The result here is significant precisely because we can describe what it found without pretending it solved the whole puzzle.